These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16291747)

  • 41. Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene.
    Vieira SA; Deininger MW; Sorour A; Sinclair P; Foroni L; Goldman JM; Melo JV
    Genes Chromosomes Cancer; 2001 Dec; 32(4):353-63. PubMed ID: 11746976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.
    Kirchner D; Duyster J; Ottmann O; Schmid RM; Bergmann L; Munzert G
    Exp Hematol; 2003 Jun; 31(6):504-11. PubMed ID: 12829026
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
    Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U
    Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.
    Goga A; McLaughlin J; Afar DE; Saffran DC; Witte ON
    Cell; 1995 Sep; 82(6):981-8. PubMed ID: 7553858
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells.
    Coppo P; Flamant S; De Mas V; Jarrier P; Guillier M; Bonnet ML; Lacout C; Guilhot F; Vainchenker W; Turhan AG
    Br J Haematol; 2006 Jul; 134(2):171-9. PubMed ID: 16846476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
    Kim JH; Chu SC; Gramlich JL; Pride YB; Babendreier E; Chauhan D; Salgia R; Podar K; Griffin JD; Sattler M
    Blood; 2005 Feb; 105(4):1717-23. PubMed ID: 15486067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
    Deutsch E; Jarrousse S; Buet D; Dugray A; Bonnet ML; Vozenin-Brotons MC; Guilhot F; Turhan AG; Feunteun J; Bourhis J
    Blood; 2003 Jun; 101(11):4583-8. PubMed ID: 12576338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells.
    Sonoyama J; Matsumura I; Ezoe S; Satoh Y; Zhang X; Kataoka Y; Takai E; Mizuki M; Machii T; Wakao H; Kanakura Y
    J Biol Chem; 2002 Mar; 277(10):8076-82. PubMed ID: 11779872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
    Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
    Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Critical role for Gab2 in transformation by BCR/ABL.
    Sattler M; Mohi MG; Pride YB; Quinnan LR; Malouf NA; Podar K; Gesbert F; Iwasaki H; Li S; Van Etten RA; Gu H; Griffin JD; Neel BG
    Cancer Cell; 2002 Jun; 1(5):479-92. PubMed ID: 12124177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
    Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
    Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA
    Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras.
    Sánchez-García I; Martín-Zanca D
    J Mol Biol; 1997 Mar; 267(2):225-8. PubMed ID: 9096220
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Munthe HA; Verfaillie CM
    Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.
    Mayerhofer M; Valent P; Sperr WR; Griffin JD; Sillaber C
    Blood; 2002 Nov; 100(10):3767-75. PubMed ID: 12393646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells.
    Dou QP; McGuire TF; Peng Y; An B
    J Pharmacol Exp Ther; 1999 May; 289(2):781-90. PubMed ID: 10215653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.